ARTICLE | Clinical News

Sustained-release travoprost: Phase IIb data

November 2, 2015 8:00 AM UTC

Top-line data from a double-blind, U.S. Phase IIb trial in 73 patients showed that 0.36 mg OTX-TP reduced IOP from baseline to day 60 by 4.8 mmHg vs. 6.4 mmHg for twice-daily timolol eye drops. At day...